• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer

    Author(s)
    Zalcberg, John R.
    Rosen, Lee S.
    Abdi, Ehtesham
    Davis, Ian D.
    Gutheil, John
    Schnell, Frederick M.
    Cesano, Alessandra
    Gayko, Urte
    Chen, Mon-Gy
    Clarke, Stephen
    Griffith University Author(s)
    Abdi, Ehtesham
    Year published
    2008
    Metadata
    Show full item record
    Abstract
    We would like to address questions raised in Dr Haines’ Letter to the Editor published July 1, 2007,1 regarding the study, “Palifermin reduces the incidence of mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.”2 With respect to the choice of treatment regimen used, the particular fluorouracil / leucovorin (FU/ LV, Mayo) regimen used in this study was widely used both in the United States and Australia at the time the study was designed and conducted. The study commenced in the mid 1990s, with the final patient enrolled onto the treatment phase of the trial in May 2000. Dr ...
    View more >
    We would like to address questions raised in Dr Haines’ Letter to the Editor published July 1, 2007,1 regarding the study, “Palifermin reduces the incidence of mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.”2 With respect to the choice of treatment regimen used, the particular fluorouracil / leucovorin (FU/ LV, Mayo) regimen used in this study was widely used both in the United States and Australia at the time the study was designed and conducted. The study commenced in the mid 1990s, with the final patient enrolled onto the treatment phase of the trial in May 2000. Dr Haines cites a study by Wang et al,3 however this was not published until after our study had completed accrual. On the other hand, a much larger study involving 372 patients published in 1994 in this journal,4 suggested that the Mayo schedule as used in this study2 was preferable to the original, weekly Roswell Park regimen of FU and folinic acid, on the basis of similar effectiveness with reduced toxicity.
    View less >
    Journal Title
    Journal of Clinical Oncology
    Volume
    26
    Issue
    8
    Publisher URI
    http://jco.ascopubs.org/
    DOI
    https://doi.org/10.1200/JCO.2007.15.4492
    Copyright Statement
    Self-archiving of the author-manuscript version is not yet supported by this journal. Please refer to the journal link for access to the definitive, published version or contact the author[s] for more information.
    Subject
    Clinical sciences
    Oncology and carcinogenesis
    Publication URI
    http://hdl.handle.net/10072/23906
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander